<DOC>
	<DOC>NCT00831714</DOC>
	<brief_summary>The main goal is to provide additional information to the risk-benefit assessment of the drug.</brief_summary>
	<brief_title>Xarelto for VTE Prophylaxis After Hip or Knee Arthroplasty</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Female and male patients who will undergo elective hip or knee arthroplasty. Exclusion criteria must be read in conjunction with the local product information.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Prophylaxis of Venous Thromboembolism</keyword>
</DOC>